Barington Capital wants Bath & Body Works sold. The market gave the stock a 2-to-3% pop in after-hours trading Thursday. Neither reaction fully captures what is actually happening here, or what the right trade is.
The Catalyst Is Real. The Power Is Not.
Barington CEO James Mitarotonda disclosed a stake of approximately one million shares in an interview with Bloomberg. With roughly 201.65 million shares outstanding, that position represents less than half a percent of the company. Barington cannot force a board vote, cannot block a poison pill, and cannot compel management to hire bankers. What it can do is make noise, and Mitarotonda is good at that.
He argues the Columbus, Ohio-based retailer is undervalued, has been hampered by unstable management, and should retain advisers to shop itself. Barington is also seeking board representation and intends to issue a letter to directors in the coming weeks. A letter is not a lever. It is a signal, and signals have a way of fading when the underlying stock has problems that go beyond who sits in the boardroom.
The stock has fallen nearly 13% so far this year. The company has been navigating a challenging consumer spending environment while pursuing a turnaround under CEO Daniel Heaf, who took over in May 2025, with a focus on product innovation and enhancing its digital platform. In August, Bath & Body Works forecast a wider-than-expected decline in current-quarter sales hurt by weak store traffic as well as broader weakness in mall traffic, Reuters reported.
Where the Edge Lives
Here is what Barington does have: a credible argument. Mitarotonda said the company’s market position, brand strength, and cash generation should attract significant buyer interest, including from private equity. Despite these operational headwinds, Mitarotonda offered a measured endorsement of current CEO Daniel Heaf, while maintaining that management must act far more decisively on capital allocation. A brand with genuine consumer loyalty, a sub-$4 billion market cap, and visible free cash flow is exactly the kind of target that catches a private equity firm’s attention, especially in a softer rate environment.
According to 19 analysts polled by S&P Global, the average rating for BBWI stock is “Hold,” with a 12-month price target of $24.06.
Why Options, Not Shares
Buying BBWI outright here means taking on real fundamental risk alongside a speculative catalyst. Store traffic is weak. The turnaround is early. And Barington holds less than half a percent of the float, which means the board can ignore the letter entirely and pay no legal price for doing so. The stock’s 52-week range of $14.28 to $32.32 tells you how wide the outcome distribution is.
A long-dated call debit spread, targeting January 2027 or later expirations, is the better structure. It defines your maximum loss to the premium paid, keeps you positioned for a meaningful re-rating if a deal materializes, and sidesteps the scenario where Barington’s letter lands with a thud and the stock drifts back toward its August lows. Short-dated BBWI options can move quickly around company news and sector moves, which cuts both ways. Going further out on the calendar reduces the risk that a slow-moving activist campaign eats your theta before anything happens.
The Beast Verdict
The Barington campaign is a real catalyst with a meaningful fundamental case underneath it. The brand has value. The balance sheet generates cash. Private equity interest is plausible. But a sub-0.5% stake does not make a deal inevitable, and owning the shares exposes you to continued fundamental deterioration if the board does nothing. A defined-risk call spread with a longer expiration captures the upside if a sale process emerges, limits the damage if it does not, and gives this thesis the time it will almost certainly need to play out. That is the trade.
